Cefpodoxime 10μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes

APMIS

Volumn 119, Issue 6, 2011, Pages 356-363

  Limnios, Athena ^a   Tapsall, John ^a   Kahlmeter, Jenny ^b   Hogan, Tiffany ^a   Ray, Sanghamitra ^a   Lam, Anne ^a   Unemo, Magnus ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimicrobial resistance (AMR) testing and surveillance; Cefpodoxime; Disc diffusion; Neisseria gonorrhoeae; penA mosaic allele

Indexed keywords

CEFIXIME; CEFPODOXIME; CEFTRIAXONE; PENICILLIN BINDING PROTEIN 2A;

AGAR DILUTION; ALLELE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; SCREENING TEST;

ALLELES; ANTI-BACTERIAL AGENTS; CEFIXIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; GONORRHEA; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; PENICILLIN-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 79955951019     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02729.x     Document Type: Article

References (25)

1. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.
2. Tapsall JW. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci. Sex Transm Infect 2009;85:256-8.
3. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009;10:555-77.
4. Lindberg R, Fredlund H, Nicholas R, Unemo M. Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime and ceftriaxone: association with genetic polymorphisms in penA, mtrR, porB1b, and ponA. Antimicrob Agents Chemother 2007;51:2117-22.
5. Takahata S, Senju N, Osaki Y, Yoshida T, Ida T. Amino acid substitutions of mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 2006;50:3638-45.
6. Zhao S, Duncan M, Tomberg J, Davies C, Unemo M, Nicholas RA. Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2009;53:3744-51.
7. Tomberg J, Unemo M, Davies C, Nicholas RA. Molecular and structural analysis of mosaic variants of penicillin-binding protein 2 conferring decreased susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae: role of epistatic mutations. Biochemistry 2010;49:8062-70.
8. Golparian D, Hellmark B, Fredlund H, Unemo M. Emergence, spread and characteristics of Neisseria gonorrhoeae isolates with in vitro decreased susceptibility and resistance to extended-spectrum cephalosporins in Sweden. Sex Transm Infect 2010;86:454-60.
9. Whiley DM, Jacobsson S, Tapsall JW, Nissen MD, Sloots TP, Unemo M. Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J Antimicrob Chemother 2010;65:2543-7.
10. Lo JYC, Ho KM, Leung AOC, Tiu FS, Tsang GK, Lo AC, et al. Ceftibuten resistance and treatment failure in gonococcal infection. Antimicrob Agent Chemother 2008;52:3564-7.
11. Yokoi S, Deguchi T, Ozawa T, Yasuda M, Ito S, Kubota Y, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007;13:1275-7.
12. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Available online.
13. Whiley DM, Limnios EA, Ray S, Sloots TP, Tapsall JW. Diversity of penA alterations and subtypes in Neisseria gonorrhoeae strains from Sydney, Australia, that are less susceptible to ceftriaxone. Antimicrob Agents Chemother 2007;51:3111-6.
14. Osaka K, Takakura T, Narukawa K, Takahata M, Endo K, Kiyota H, et al. Analysis of amino acid sequences of penicillin-binding protein 2 in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime and ceftriaxone. J Infect Chemother 2008;14:195-203.
15. Lee SG, Lee H, Jeong SH, Yong D, Chung GT, Lee YS, et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. J Antimicrob Chemother 2010;65:669-75.
16. Bala M, Tapsall JW, Limnios A, Sood S, Ray K. Experience with an external quality assurance scheme for antimicrobial susceptibility testing of Neisseria gonorrhoeae in India, 2001-2007. Epidemiol Infect 2010;138:69-75.
17. Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009;63:1142-51.
18. WHO. GASP Document, "Rationale and applications for the current (2008) WHO panel of Neisseria gonorrhoeae for antimicrobial resistance surveillance for public health purposes, and instructions for their use", Technical document D007-0408-1. Sydney: WHO Collaborating Centre for STD, 2008.
19. Tapsall JW. Antimicrobial testing and applications in the pathogenic Neisseria. In: Merlino J, editor. Antimicrobial Susceptibility Testing: Methods and Practices with an Australian Perspective. Sydney: Australian Society for Microbiology, 2004: 175-88.
20. The CDS Antibiotic Susceptibility Test. Available at: accessed 8 February 2011.
21. Tapsall JW, Phillips EA. The sensitivity of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhoea. Pathology 1995;27:64-6.
22. Whiley SM, Bates J, Limnios A, Nissen MD, Tapsall J, Sloots TP. Use of a novel screening PCR indicates presence of Neisseria gonorrhoeae with a mosaic penA gene sequence in Australia. Pathology 2007;39:445-6.
23. Unemo M, Olcén P, Fredlund H, Thulin S. Real-time PCR and subsequent pyrosequencing for screening of penA mosaic alleles and prediction of reduced susceptibility to expanded-spectrum cephalosporins in Neisseria gonorrhoeae. APMIS 2008;116:1004-8.
24. Pandori M, Barry PM, Wu A, Ren A, Whittington WL, Liska S, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009;53:4032-4.
25. Ochiai S, Ishiko H, Yasuda M, Deguchi T. Rapid detection of the mosaic structure of the Neisseria gonorrhoeae penA gene, which is associated with decreased susceptibilities to oral cephalosporins. J Clin Microbiol 2008;46:1804-10.